Condition: Spinal Cord Injury, Acute · Spinal Cord Injury at C4 Level With Complete Lesion · Spinal Cord Injury at C5-C7 Level With Complete Lesion · Sponsor: S.Biomedics Co., Ltd.
This study intends to evaluate the safety and exploratory efficacy of transplantation therapy using neural precursor cells (PSA-NCAM(+) NPC) derived from the human embryonic stem cell line for the treatment of paralysis and other related symptoms from sub-acute spinal cord injury.
This description comes directly from the study's public registry record.
Sarang Kim · +82 70-2205-0023 · info@sbiomedics.com
Always discuss trial participation with your own doctor first.
| Ajou University Hospital | Suwon, Gyeonggido, South Korea | Recruiting |
| Yonsei University Health System, Severance Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04812431